CD19 and leukemia: Next, we successfully constructed a CD19 specific CAR combined with IL-15-IL-15Ra fusion proteins and examined its cell viability in vitro and immunotoxicity in xenograft mouse models, which provide a candidate tool for clinical leukemia treatment.